Results 101 to 110 of about 369,698 (260)

Long‐Term (5‐Years) Outcomes of Current Drug‐Eluting Stents in Percutaneous Coronary Intervention: A Network Meta‐Analysis of Randomized Controlled Trials

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Various drug‐eluting stents (DES) are currently used for percutaneous coronary intervention (PCI). However, long‐term trials reveal inconsistent results in head‐to‐head comparisons. Aims To conduct a network meta‐analysis of relevant trials to assess the performance of different DES currently used in PCI.
Aman Goyal, Humza Saeed, Sonia Hurjkaliani, Yusra Mashkoor, Abdullah, Gauranga Mahalwar, Ankur Kalra, Grant W. Reed   +7 more
wiley   +1 more source

Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application

Chronic Diseases and Translational Medicine, EarlyView.
Donanemab, approved by the U.S. FDA in July 2024, targets amyloid plaques in the brain to treat Alzheimer's disease in patients with mild cognitive impairment or mild dementia. ABSTRACT Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD).
Nandhini Jayaprakash, Karthikeyan Elumalai   +1 more
wiley   +1 more source

Contemporary Perspectives on Chronic Renal Disorders

Chronic Diseases and Translational Medicine, EarlyView.
ABSTRACT The prevalence of renal diseases and its associated burden on healthcare have tremendously risen in the past few years. From simple markers assessing kidney function, current renal research delves into understanding the diseases at the cellular and molecular levels and not just at treating, but at improving quality of life, arresting ...
Deenadhayalan Ashok, Poornima Ajay Manjrekar, Bhushan C. Shetty, Sujina S. S, Rukmini Mysore Srikantiah, Sowndarya Kollampare   +5 more
wiley   +1 more source

Disruption of salt bridge interactions in the inter‐domain cleft of the tubulin‐like protein FtsZ of Escherichia coli makes cells sensitive to the cell division inhibitor PC190723

Cytoskeleton, EarlyView.
Abstract FtsZ forms a ring‐like assembly at the site of division in bacteria. It is the first protein involved in the formation of the divisome complex to split the cell into two halves, indicating its importance in bacterial cell division. FtsZ is an attractive target for developing new anti‐microbial drugs to overcome the challenges of antibiotic ...
Sakshi Mahesh Poddar, Joyeeta Chakraborty, Pananghat Gayathri, Ramanujam Srinivasan   +3 more
wiley   +1 more source

Interaction Between Actin and Microtubules During Plant Development

Cytoskeleton, EarlyView.
ABSTRACT The dynamic interaction between actin filaments (AFs) and microtubules (MTs) plays a crucial role in regulating key developmental and physiological processes in plant cells, particularly in the formation of specialized cell types with distinct shapes and functions, such as pollen tubes, trichomes, and leaf epidermal cells.
Zining Wu, Lidong Gao, M. Arif Ashraf, Qiong Nan   +3 more
wiley   +1 more source

Pharmacokinetics, Safety, and Tolerability of Single‐Dose Dazukibart in Healthy Adults in China and Japan: Results From 2 Randomized, Double‐Blind, Phase 1 Studies

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Dazukibart is a humanized monoclonal antibody selectively targeting interferon‐β. The pharmacokinetics (PK), safety, tolerability, and immunogenicity of dazukibart were evaluated in 2 double‐blind, randomized, placebo‐controlled, single‐dose, Phase 1 studies in healthy adults in China (Study 1: N = 18; dazukibart 900 mg = 15; placebo = 3) and ...
Naihan Chen, Yamato Sano, Xiaohong Wang, Shuiyi Hu, Junichi Tabira, Xin Luo, Hiroki Yoshimatsu, John Prybylski, Myron Chu, Haiyan Li, Kenji Takazawa   +10 more
wiley   +1 more source

A 2‐Part, Open‐Label, Phase 1 Bioequivalence and Food‐Effect Study of Ubrogepant in Healthy Adult Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract This Phase 1 study of ubrogepant was conducted to establish the bioequivalence (BE) of the 50‐ and 100‐mg to‐be‐marketed (TBM) tablet formulations with the clinical trial (CT) 100‐mg tablet formulation and evaluate the food effect on the bioavailability of the 100‐mg TBM tablet. This 2‐part study enrolled healthy participants aged 18‐45 years.
Ramesh Boinpally, Joel M. Trugman
wiley   +1 more source

Bioequivalence of a Donepezil/Memantine 10/20 mg Fixed‐Dose Combination Versus Single‐Component Tablets in Healthy Korean Males

Clinical Pharmacology in Drug Development, EarlyView.
Abstract A fixed‐dose combination (FDC) tablet formulation of donepezil/memantine (10/20 mg) was developed to improve medication compliance in patients with Alzheimer's disease (AD). This study compared the pharmacokinetic (PK) characteristics and safety profiles of an FDC formulation (donepezil/memantine [10/20 mg]) and single components (SCs) of ...
Minkyu Choi, Byung Hak Jin, Do Hoon Keum, Kyoung Hoon Mo, Min Soo Park, Juhwan Lee, Sungjin Park, Choon Ok Kim   +7 more
wiley   +1 more source

Post-stroke sensory hypersensitivity: insights from lesion-symptom and disconnection mapping. [PDF]

Brain Commun
Thielen H, Tuts N, Welkenhuyzen L, Lemmens R, Wibail A, Huenges Wajer IMC, Lafosse C, Mantini D, Gillebert CR.   +8 more
europepmc   +1 more source

Hypersensitivity to Neomycin [PDF]

BMJ, 1965
Michael Feiwel, Donald Munro-Ashman
openaire   +3 more sources